amlodipine has been researched along with Kidney Diseases in 59 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease." | 9.16 | [Protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease]. ( Gao, M; Han, X; Hui, H; Li, K; Li, Z; Wang, J, 2012) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 9.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency." | 9.13 | Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. ( Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Suzuki, T; Ueda, Y, 2008) |
| "To assess whether treatment with a dihydropyridine calcium antagonist can prevent the development of hypertension and renal dysfunction after heart transplantation, 38 patients receiving cyclosporine for immunosuppression were randomized shortly after cardiac transplantation to placebo or amlodipine 2." | 9.12 | Prevention of renal dysfunction and hypertension by amlodipine after heart transplant. ( Coletta, E; Davies, RA; Leenen, FH, 2007) |
| " Therefore, we investigated the beneficial effects of cilnidipine on renal injury in Dahl salt-sensitive (Dahl S) rats fed a high-sucrose diet (HSD), which mimics metabolic syndrome, and compared them with the effects of an L-type CCB, amlodipine." | 7.73 | The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. ( Enomoto, A; Konda, T; Matsushita, J; Moriyama, T; Takahara, A, 2005) |
| " In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial." | 5.31 | Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. ( Bianchetti, MG; Bianda, ND; Casaulta Aebischer, C; Franscini, LM; Pfister, R; von Vigier, RO, 2001) |
| "Albuminuria was significantly reduced, compared with baseline values, with the lercanidipine + enalapril combination over the entire study period; at month 3, month 6 and month 12, changes from baseline were: -162." | 5.22 | Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. ( Calvo, C; Espinel, E; Esteban, R; Macias, JF; Mateos, L; Robles, NR; Sobrino, J, 2016) |
| "A total of 439 hypertensive patients with metabolic syndrome and/or diabetes mellitus were randomized to 2 groups: group 1--ramipril (ACE-I) or perindopril and group 2--losartan (ARB)." | 5.19 | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). ( Soucek, M; Spinar, J; Vitovec, J, 2014) |
| "To evaluate the protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease." | 5.16 | [Protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease]. ( Gao, M; Han, X; Hui, H; Li, K; Li, Z; Wang, J, 2012) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 5.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164)." | 5.14 | CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. ( Alcaraz, J; Appel, LJ; Bakris, GL; Bhatnagar, V; Brophy, VH; Contreras, G; Garcia, EP; Hiremath, L; Lipkowitz, MS; Middleton, JP; Norris, KC; O'Connor, DT; Richard, E; Wright, J, 2010) |
| "The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency." | 5.13 | Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. ( Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Suzuki, T; Ueda, Y, 2008) |
| "Based on results of large-scale controlled trials of irbesartan (I), valsartan (V) and amlodipine (A) (PRIME and MARVAL) we carried out the Markov s modeling of their pharmacoeconomic parameters in arterial hypertension (AH) combined with diabetes mellitus type 2 (DM 2) and microalbuminuria (MAU) projected for 8-years perspective." | 5.13 | [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus]. ( Belousov, DIu; Belousov, IuB; Shestakova, MV, 2008) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| "The African American Study of Kidney Disease and Hypertension was a multicenter trial comparing the effects of 2 levels of blood pressure control (usual or low goal) and initial therapy with metoprolol, ramipril, or amlodipine." | 5.12 | Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. ( Gadegbeku, CA; Greene, T; Hall, Y; Jones, K; Kusek, JW; Lash, JP; Sika, M; Unruh, M; Wang, X, 2006) |
| "To assess whether treatment with a dihydropyridine calcium antagonist can prevent the development of hypertension and renal dysfunction after heart transplantation, 38 patients receiving cyclosporine for immunosuppression were randomized shortly after cardiac transplantation to placebo or amlodipine 2." | 5.12 | Prevention of renal dysfunction and hypertension by amlodipine after heart transplant. ( Coletta, E; Davies, RA; Leenen, FH, 2007) |
| "Losartan induced a drastic decrease in proteinuria accompanied by a reduction in urinary excretion of TGF-beta in patients with non-diabetic proteinuric renal diseases." | 5.10 | Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. ( Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F, 2003) |
| "The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy." | 5.08 | Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998) |
| "During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan." | 3.88 | Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. ( Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018) |
| "Two hundred eighty-six outpatients prescribed three different CCBs (benidipine [CAS 91599-74-5], amlodipine [CAS 111470-99-6] and controlled release nifedipine (nifedipine CR) [CAS 21829-25-4]) for hypertension in combination with ARBs during a 4-year period were registered in a retrospective comparative study." | 3.76 | Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study. ( Futenma, A; Imai, H; Kimura, Y; Maeda, K; Miura, N; Suga, N; Yamada, H, 2010) |
| " Therefore, we investigated the beneficial effects of cilnidipine on renal injury in Dahl salt-sensitive (Dahl S) rats fed a high-sucrose diet (HSD), which mimics metabolic syndrome, and compared them with the effects of an L-type CCB, amlodipine." | 3.73 | The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. ( Enomoto, A; Konda, T; Matsushita, J; Moriyama, T; Takahara, A, 2005) |
| "Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes." | 3.73 | [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005) |
| "Proteinuria was positively correlated with circulating AGE and sRAGE levels in our subjects." | 2.76 | Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Takeuchi, M; Ueda, Y; Yamagishi, S, 2011) |
| "Pretreatment with amlodipine created no difference in both variables (p > 0." | 2.71 | Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration. ( Altun, B; Arici, M; Cağlar, S; Erdem, Y; Kes, S; Turgan, C; Usalan, C; Yasavul, U, 2003) |
| " A side effect of mild headache was reported by one patient (2." | 2.67 | Efficacy and safety of amlodipine in hypertensive patients with renal dysfunction. ( Abe, K; Iimura, I; Ishii, M; Saruta, T, 1994) |
| "Amlodipine, a dihydropyridine calcium antagonist, was synthesized in an attempt to develop a compound with a pharmacokinetic profile characteristic of this class, which would also have an increased oral bioavailability and extended clearance time." | 2.38 | The pharmacokinetic profile of amlodipine. ( Abernethy, DR, 1989) |
| "Secondary hypertension was suspected and autoimmune workup was positive for anticardiolipin IgG and lupus anticoagulant." | 1.51 | Chronic thrombotic microangiopathy secondary to antiphospholipid syndrome, presenting with severe hypertension and chronic renal impairment. ( Angkodjojo, S; Tan, PH; Yee, Y, 2019) |
| "Hypertension is present in nearly 80% of dialysis patients yet adequately controlled in less than half." | 1.34 | ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. ( Coyne, DW; Nath, V; Zheng, S, 2007) |
| "Heart failure was four times more frequent in these patients with renal disease than in other hypertensives." | 1.33 | [Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. ( Aguilar-Llopis, A; Arístegui-Urrestarazu, R; Cosín-Aguilar, J; Hernándiz-Martínez, A; Masramón-Morell, X; Rodríguez-Padial, L; Zamorano-Gómez, JL, 2006) |
| "Although fitting orders to renal function avoids overdosage and therefore iatrogenic risk, dosage adjustment is rarely made." | 1.32 | Assessing residents' prescribing behavior in renal impairment. ( Brücker, G; Deray, G; Launay-Vacher, V; Levu, S; Ravaud, P; Salomon, L, 2003) |
| " In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial." | 1.31 | Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. ( Bianchetti, MG; Bianda, ND; Casaulta Aebischer, C; Franscini, LM; Pfister, R; von Vigier, RO, 2001) |
| "Amlodipine was injected intraperitoneally in a dose of 5 mg/kg/day, either once daily at 8." | 1.30 | Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats. ( Kränzlin, B; Lemmer, B; Schmidt, T; Schnecko, A; Voll, C; Witte, K, 1999) |
| "Amlodipine was more effective than enalapril in reducing proteinuria and glomerulosclerosis in the group that was started on drug therapy eight weeks after surgery." | 1.29 | Antihypertensive agents and renal protection: calcium channel blockers. ( Hayashi, K; Kanno, Y; Konishi, K; Saruta, T, 1996) |
| "Amlodipine was administered as 14 single 5-mg oral daily doses to 27 male subjects with renal function ranging from normal to haemodialysis-dependent." | 1.28 | Pharmacokinetics of amlodipine in renal impairment. ( Carmody, M; Donohue, J; Doyle, GD; Greb, H; Laher, M; Volz, M, 1989) |
| " The elimination half-life was of the order of 50 h, similar to previously observed values, and did not vary with differences in renal function." | 1.27 | Pharmacokinetics of amlodipine in renal impairment. ( Carmody, M; Donohoe, JF; Doyle, GD; Greb, H; Kelly, JG; Laher, MS; Volz, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.08) | 18.7374 |
| 1990's | 7 (11.86) | 18.2507 |
| 2000's | 27 (45.76) | 29.6817 |
| 2010's | 22 (37.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yee, Y | 1 |
| Angkodjojo, S | 1 |
| Tan, PH | 1 |
| Liu, J | 1 |
| Yasuno, S | 1 |
| Oba, K | 1 |
| Konda, M | 1 |
| Ichihara, C | 1 |
| Kitao, H | 1 |
| Kuwabara, Y | 2 |
| Ueshima, K | 1 |
| Oguzhan, N | 1 |
| Cilan, H | 1 |
| Sipahioglu, M | 1 |
| Unal, A | 1 |
| Kocyigit, I | 1 |
| Kavuncuoglu, F | 1 |
| Arikan, T | 1 |
| Akpek, M | 1 |
| Elcik, D | 1 |
| Sahin, O | 1 |
| Gulme, E | 1 |
| Pala, C | 1 |
| Tokgoz, B | 1 |
| Utas, C | 1 |
| Oguzhan, A | 1 |
| Oymak, O | 1 |
| Spinar, J | 1 |
| Vitovec, J | 1 |
| Soucek, M | 1 |
| Sweiss, N | 1 |
| Sharma, K | 1 |
| Robles, NR | 1 |
| Calvo, C | 2 |
| Sobrino, J | 1 |
| Espinel, E | 1 |
| Esteban, R | 1 |
| Mateos, L | 1 |
| Macias, JF | 1 |
| Tepel, M | 1 |
| Hopfenmueller, W | 1 |
| Scholze, A | 1 |
| Maier, A | 1 |
| Zidek, W | 1 |
| Nakamura, T | 2 |
| Inoue, T | 1 |
| Suzuki, T | 1 |
| Kawagoe, Y | 2 |
| Ueda, Y | 2 |
| Koide, H | 2 |
| Node, K | 1 |
| Belousov, IuB | 1 |
| Shestakova, MV | 1 |
| Belousov, DIu | 1 |
| Saruta, T | 5 |
| Hayashi, K | 4 |
| Ogihara, T | 1 |
| Nakao, K | 1 |
| Fukui, T | 1 |
| Fukiyama, K | 1 |
| Du, J | 1 |
| Fan, YY | 1 |
| Hitomi, H | 1 |
| Kiyomoto, H | 1 |
| Kimura, S | 1 |
| Kong, CZ | 1 |
| Noma, T | 1 |
| Kohno, M | 1 |
| Nishiyama, A | 1 |
| Nakano, D | 1 |
| Khan, AH | 1 |
| Sattar, MA | 1 |
| Abdullah, NA | 1 |
| Johns, EJ | 1 |
| Izzo, JL | 1 |
| Purkayastha, D | 1 |
| Hall, D | 1 |
| Hilkert, RJ | 1 |
| Bhatnagar, V | 1 |
| Garcia, EP | 1 |
| O'Connor, DT | 1 |
| Brophy, VH | 1 |
| Alcaraz, J | 1 |
| Richard, E | 1 |
| Bakris, GL | 1 |
| Middleton, JP | 1 |
| Norris, KC | 1 |
| Wright, J | 1 |
| Hiremath, L | 1 |
| Contreras, G | 1 |
| Appel, LJ | 2 |
| Lipkowitz, MS | 2 |
| Milani, G | 1 |
| Ragazzi, M | 1 |
| Simonetti, GD | 1 |
| Ramelli, GP | 1 |
| Rizzi, M | 1 |
| Bianchetti, MG | 2 |
| Fossali, EF | 1 |
| Yamada, H | 1 |
| Suga, N | 1 |
| Maeda, K | 1 |
| Kimura, Y | 1 |
| Miura, N | 1 |
| Futenma, A | 1 |
| Imai, H | 1 |
| Slagman, MC | 1 |
| Navis, G | 1 |
| Laverman, GD | 1 |
| Aritomi, S | 1 |
| Koganei, H | 1 |
| Wagatsuma, H | 1 |
| Mitsui, A | 1 |
| Ogawa, T | 1 |
| Nitta, K | 1 |
| Konda, T | 2 |
| Narumi, H | 1 |
| Takano, H | 1 |
| Shindo, S | 1 |
| Fujita, M | 1 |
| Mizuma, H | 1 |
| Komuro, I | 1 |
| Liu, W | 1 |
| Wang, W | 1 |
| Song, SW | 1 |
| Gu, XF | 1 |
| Ma, XJ | 1 |
| Su, FY | 1 |
| Zhang, H | 1 |
| Liu, AJ | 1 |
| Su, DF | 1 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Takeuchi, M | 1 |
| Yamagishi, S | 1 |
| Davis, EM | 1 |
| Wang, X | 2 |
| Greene, T | 2 |
| Astor, BC | 1 |
| Rahman, M | 3 |
| Toto, R | 1 |
| Pogue, VA | 1 |
| Wright, JT | 3 |
| Chobanian, AV | 1 |
| Takenaka, T | 1 |
| Uchida, K | 1 |
| Kojima, E | 1 |
| Gen, S | 1 |
| Nodaira, Y | 1 |
| Hoshi, H | 1 |
| Kato, N | 1 |
| Takane, H | 1 |
| Ohno, Y | 1 |
| Suzuki, H | 2 |
| Nagasu, H | 1 |
| Satoh, M | 1 |
| Fujimoto, S | 1 |
| Tomita, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Ford, CE | 1 |
| Cutler, JA | 1 |
| Davis, BR | 2 |
| Piller, LB | 1 |
| Whelton, PK | 2 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Haywood, LJ | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Oparil, S | 1 |
| Preston, R | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Hui, H | 1 |
| Li, K | 1 |
| Li, Z | 1 |
| Wang, J | 1 |
| Gao, M | 1 |
| Han, X | 1 |
| Salomon, L | 1 |
| Levu, S | 1 |
| Deray, G | 1 |
| Launay-Vacher, V | 1 |
| Brücker, G | 1 |
| Ravaud, P | 1 |
| Praga, M | 2 |
| Andrade, CF | 1 |
| Luño, J | 2 |
| Arias, M | 2 |
| Poveda, R | 2 |
| Mora, J | 1 |
| Prat, MV | 1 |
| Rivera, F | 2 |
| Galceran, JM | 2 |
| Ara, JM | 1 |
| Aguirre, R | 1 |
| Bernis, C | 1 |
| Marín, R | 2 |
| Campistol, JM | 2 |
| Arici, M | 1 |
| Usalan, C | 1 |
| Altun, B | 1 |
| Erdem, Y | 1 |
| Yasavul, U | 1 |
| Turgan, C | 1 |
| Kes, S | 1 |
| Cağlar, S | 1 |
| Homma, K | 1 |
| Kanda, T | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Kumagai, H | 2 |
| Wakino, S | 1 |
| Bernobich, E | 1 |
| Cosenzi, A | 1 |
| Campa, C | 1 |
| Zennaro, C | 1 |
| Sasso, F | 1 |
| Paoletti, S | 1 |
| Bellini, G | 1 |
| Enomoto, A | 1 |
| Matsushita, J | 1 |
| Takahara, A | 1 |
| Moriyama, T | 1 |
| Wei, L | 1 |
| Tan, J | 1 |
| Coto, E | 1 |
| Alvarez, V | 1 |
| Fernández Andrade, C | 1 |
| Vallés, M | 1 |
| Pressel, S | 1 |
| Nwachuku, C | 1 |
| Barzilay, J | 1 |
| Batuman, V | 1 |
| Eckfeldt, JH | 1 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Henriquez, M | 1 |
| Kopyt, N | 1 |
| Louis, GT | 1 |
| Saklayen, M | 1 |
| Stanford, C | 1 |
| Walworth, C | 1 |
| Ward, H | 1 |
| Wiegmann, T | 1 |
| Lash, JP | 1 |
| Gadegbeku, CA | 1 |
| Hall, Y | 1 |
| Jones, K | 1 |
| Kusek, JW | 1 |
| Sika, M | 1 |
| Unruh, M | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Cosín-Aguilar, J | 1 |
| Hernándiz-Martínez, A | 1 |
| Arístegui-Urrestarazu, R | 1 |
| Masramón-Morell, X | 1 |
| Aguilar-Llopis, A | 1 |
| Rodríguez-Padial, L | 1 |
| Zamorano-Gómez, JL | 1 |
| Liu, LL | 1 |
| Li, QX | 1 |
| Xia, L | 1 |
| Li, J | 1 |
| Shao, L | 1 |
| Leenen, FH | 1 |
| Coletta, E | 1 |
| Davies, RA | 1 |
| Zheng, S | 1 |
| Nath, V | 1 |
| Coyne, DW | 1 |
| Esnault, VL | 1 |
| Brown, EA | 1 |
| Apetrei, E | 1 |
| Bagon, J | 1 |
| DeChatel, R | 1 |
| Holdaas, H | 2 |
| Krcmery, S | 1 |
| Kobalava, Z | 1 |
| Kanno, Y | 2 |
| Okada, H | 1 |
| Ishii, M | 1 |
| Abe, K | 1 |
| Iimura, I | 1 |
| Konishi, K | 1 |
| Passavanti, G | 1 |
| Vernaglione, L | 1 |
| Mancini, A | 1 |
| Hartmann, A | 1 |
| Berg, KJ | 1 |
| Lund, K | 1 |
| Fauchald, P | 1 |
| Witte, K | 1 |
| Schnecko, A | 1 |
| Schmidt, T | 1 |
| Voll, C | 1 |
| Kränzlin, B | 1 |
| Lemmer, B | 1 |
| Atarashi, K | 1 |
| Takagi, M | 1 |
| Minami, M | 1 |
| Ishiyama, A | 1 |
| von Vigier, RO | 1 |
| Franscini, LM | 1 |
| Bianda, ND | 1 |
| Pfister, R | 1 |
| Casaulta Aebischer, C | 1 |
| Baylis, C | 1 |
| Qiu, C | 1 |
| Engels, K | 1 |
| Studney, D | 1 |
| Laher, MS | 1 |
| Kelly, JG | 1 |
| Doyle, GD | 2 |
| Carmody, M | 2 |
| Donohoe, JF | 1 |
| Greb, H | 2 |
| Volz, M | 2 |
| Donohue, J | 1 |
| Laher, M | 1 |
| Abernethy, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])[NCT00124969] | Phase 4 | 356 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension[NCT00136851] | Phase 4 | 259 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985] | Phase 4 | 97 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amlodipine and Kidney Diseases
| Article | Year |
|---|---|
Adiponectin effects on the kidney.
Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa | 2014 |
[Novel actions of calcium channel blockers].
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Depression; Dihydropyridine | 2006 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
The pharmacokinetic profile of amlodipine.
Topics: Administration, Oral; Aging; Amlodipine; Angina Pectoris; Animals; Biological Availability; Calcium | 1989 |
25 trials available for amlodipine and Kidney Diseases
| Article | Year |
|---|---|
The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin Receptor Antagonists; Calcium | 2013 |
Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2014 |
Lercanidipine valuable effect on urine protein losses: the RED LEVEL study.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Bli | 2016 |
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.
Topics: Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Chronic Disease | 2008 |
Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressu | 2008 |
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Co | 2008 |
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2009 |
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzazepines; Chron | 2010 |
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
Topics: Aged; Alleles; Amlodipine; Black or African American; Blood Pressure; Cytochrome P-450 CYP3A; Female | 2010 |
Superior palatability of crushed lercanidipine compared with amlodipine among children.
Topics: Administration, Oral; Amlodipine; Calcium Channel Blockers; Child; Child, Preschool; Dihydropyridine | 2010 |
Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Fe | 2011 |
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive A | 2011 |
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Female; | 2011 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
[Protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease].
Topics: Aged; Amlodipine; Contrast Media; Coronary Angiography; Coronary Disease; Female; Humans; Kidney Dis | 2012 |
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blocke | 2003 |
Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration.
Topics: Amlodipine; Calcium Channel Blockers; Contrast Media; Coronary Angiography; Female; Glutathione Tran | 2003 |
Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2004 |
Clinical observation on Breviscapine in treating hypertension patients complicated with micro-albuminuria of renal impairment.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; | 2005 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Press | 2006 |
Prevention of renal dysfunction and hypertension by amlodipine after heart transplant.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Creatini | 2007 |
The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Coh | 2008 |
Efficacy and safety of amlodipine in hypertensive patients with renal dysfunction.
Topics: Adult; Aged; Amlodipine; Female; Humans; Hypertension; Japan; Kidney Diseases; Male; Middle Aged; Tr | 1994 |
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Ove | 1998 |
30 other studies available for amlodipine and Kidney Diseases
| Article | Year |
|---|---|
Chronic thrombotic microangiopathy secondary to antiphospholipid syndrome, presenting with severe hypertension and chronic renal impairment.
Topics: Adult; Amlodipine; Anticoagulants; Antihypertensive Agents; Antiphospholipid Syndrome; Diagnosis, Di | 2019 |
Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardi | 2018 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia | 2009 |
Effect of calcium channel blockade on adrenergically induced renal vasoconstriction in rat models of renal impairment.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Diabetic Nephropathies; Disease Models, Animal; Drug | 2009 |
Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Creatinine; Dih | 2010 |
Reversible effects of diuretics added to renin-angiotensin-aldosterone system blockade: impact on interpretation of long-term kidney function outcome.
Topics: Amlodipine; Chronic Disease; Data Interpretation, Statistical; Diuretics; Humans; Hydrochlorothiazid | 2010 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazol | 2011 |
Mixed messages on blood pressure goals.
Topics: Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Glomerular Filtratio | 2011 |
Amlodipine and loop diuretics as the second anti-hypertensive medication for the treatment of hypertension with chronic kidney diseases.
Topics: Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2011 |
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Topics: Amlodipine; Animals; Arterioles; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; | 2012 |
Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Female; Glomerular Filtration Rate; Humans; Hyp | 2012 |
Assessing residents' prescribing behavior in renal impairment.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents | 2003 |
Antihypertensive treatment and renal damage: amlodipine exerts protective effect through the polyol pathway.
Topics: Administration, Oral; Amlodipine; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen Type | 2004 |
The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Ca | 2005 |
[Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2005 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
[Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease].
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Di | 2006 |
Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats.
Topics: Amlodipine; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrogen; Calci | 2007 |
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2007 |
Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Hypertension; Kidney; Kidney Diseases; Nephrectomy | 1994 |
Antihypertensive agents and renal protection: calcium channel blockers.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Calcium Chan | 1996 |
Effects of amlodipine and enalapril alone and in combination on glomerular hemodynamics in a hypertensive patient with unilaterally contracted kidney.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Interacti | 1998 |
Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats.
Topics: Albumins; Amlodipine; Animals; Animals, Genetically Modified; Blood Pressure; Calcium; Calcium Chann | 1999 |
Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Calcium | 1999 |
Hypertensive African Americans with kidney disease should seek advice from doctor about blood pressure medication.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African Amer | 2001 |
Antihypertensive efficacy of amlodipine in children with chronic kidney diseases.
Topics: Adolescent; Adult; Age Factors; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child We | 2001 |
Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; C | 2001 |
Pharmacokinetics of amlodipine in renal impairment.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Female; Half-Life; Humans; Kidney Diseases; Male; | 1988 |
Pharmacokinetics of amlodipine in renal impairment.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Female; Half-Life; Humans; Kidney Diseases; Male; | 1989 |